Find in Library

Breast milk is the combination of bioactive compounds and microflora that promote newborn’s proper growth, gut flora, and immunity. Thus, it is always considered the perfect food for newborns. Amongst their bioactives, probiotic communities—especially lactic acid bacteria (LAB)—are characterized from breast milk over the first month of parturition. In this study, seven LAB were characterized phenotypically and genotypically as <i>Levilactobacillus brevis</i> BDUMBT08 (MT673657), <i>L. gastricus</i> BDUMBT09 (MT774596), <i>L. paracasei</i> BDUMBT10 (MT775430), <i>L. brevis</i> BDUMBT11 (MW785062), <i>L. casei</i> BDUMBT12 (MW785063), <i>L. casei</i> BDUMBT13 (MW785178), and <i>Brevibacillus brevis</i> M2403 (MK371781) from human breast milk. Their tolerance to lysozyme, acid, bile, gastric juice, pancreatic juice, and NaCl and potential for mucoadhesion, auto-aggregation, and co-aggregation with pathogens are of great prominence in forecasting their gut colonizing ability. They proved their safety aspects as they were negative for virulence determinants such as hemolysis and biofilm production. Antibiogram of LAB showed their sensitivity to more than 90% of the antibiotics tested. Amongst seven LAB, three isolates (<i>L. brevis</i> BDUMBT08 and BDUMBT11, and <i>L. gatricus</i> BDUMBT09) proved their bacteriocin producing propensity. Although the seven LAB isolates differed in their behavior, their substantial probiotic properties with safety could be taken as promising probiotics for further studies to prove their in vivo effects, such as health benefits, in humans.